ArticleAdvances in therapy2025

Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy.

Jeroen Hendrikus Jacobus Paulissen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.